Medscape is available in 5 Language Editions – Choose your Edition here.


Precocious Puberty

  • Author: Paul B Kaplowitz, MD, PhD; Chief Editor: Stephen Kemp, MD, PhD  more...
Updated: Jun 24, 2016


Precocious puberty refers to the appearance of physical and hormonal signs of pubertal development at an earlier age than is considered normal. For many years, puberty was considered precocious in girls younger than 8 years; however, recent studies indicate that signs of early puberty (breasts and pubic hair) are often present in girls (particularly black girls) aged 6-8 years. For boys, onset of puberty before age 9 years is considered precocious.

Early onset of puberty can cause several problems. The early growth spurt initially can cause tall stature, but rapid bone maturation can cause linear growth to cease too early and can result in short adult stature. The early appearance of breasts or menses in girls and increased libido in boys can cause emotional distress for some children.

Premature pubarche and premature thelarche are 2 common, benign, normal variant conditions that can resemble precocious puberty but are nonprogressive or very slowly progressive. Premature thelarche refers to the isolated appearance of breast development, usually in girls younger than 3 years; premature pubarche refers to appearance of pubic hair without other signs of puberty in girls or boys younger than 7-8 years. A thorough history, physical examination, and growth curve review can help distinguish these normal variants from true sexual precocity.

If the history, physical examination, and laboratory data suggest that a child exhibits early and sustained evidence of pubertal maturation, the clinician must differentiate central precocious puberty (CPP) from precocious pseudopuberty. Central precocious puberty, which is gonadotropin-dependent, is the early maturation of the entire hypothalamic-pituitary-gonadal (HPG) axis, with the full spectrum of physical and hormonal changes of puberty. Precocious pseudopuberty is much less common and refers to conditions in which increased production of sex steroids is gonadotropin-independent (see Precocious Pseudopuberty). Correct diagnosis of the etiology of sexual precocity is critical, because evaluation and treatment of patients with precocious pseudopuberty is quite different than that for patients with central precocious puberty.



Most patients, particularly girls suspected of having central precocious puberty, are otherwise healthy children whose pubertal maturation begins at the early end of the normal distribution curve. CNS imaging studies of these otherwise healthy 6-year-old to 8-year-old girls usually reveal no structural abnormalities. A study of 200 girls in France identified abnormal brain imaging findings in 2% of girls whose onset of puberty was between age 6-8 years and in 20% of girls whose onset of puberty was before age 6 years.[1] A smaller study from the United Kingdom reported abnormal findings in 15% of 67 girls.[2] Abnormal CT scan or MRI findings are more frequent among boys with central precocious puberty than among girls with central precocious puberty.

The onset of puberty is caused by the secretion of high-amplitude pulses of gonadotropin-releasing hormone (GnRH) by the hypothalamus. The hypothesized mechanisms that suppress onset of puberty include (1) the HPG axis, which is highly sensitive to feedback inhibition by small amounts of sex steroids, and (2) central neural pathways that suppress the release of GnRH pulses.

CNS abnormalities associated with precocious puberty include the following:

  • Tumors (eg, astrocytomas, gliomas, germ cell tumors secreting human chorionic gonadotropin [HCG])
  • Hypothalamic hamartomas
  • Acquired CNS injury caused by inflammation, surgery, trauma, radiation therapy, or abscess
  • Congenital anomalies (eg, hydrocephalus, arachnoid cysts, suprasellar cysts)

High-amplitude pulses of GnRH cause pulsatile increases in the pituitary gonadotropin-luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Increased LH levels stimulate production of sex steroids by testicular Leydig cells or ovarian granulosa cells. Pubertal levels of androgens or estrogens cause the physical changes of puberty, including penile enlargement and sexual hair in boys and breast development in girls. These levels also mediate the pubertal growth spurt. Increased FSH levels cause enlargement of the gonads in both sexes and eventually promote follicular maturation in girls and spermatogenesis in boys.




United States

The frequency of findings suggestive of precocious puberty in girls and boys largely depends on whether one is looking at genital hair or breast development as well as the age at which the condition is considered precocious.

In 1969, Marshall and Tanner published the results of their study of 192 white British girls.[3] These researchers stated that the average age of thelarche was 11 years and they defined precocious puberty in girls as that which started before age 8 years. No studies that looked at the age of appearance of breast and pubic hair in normal children were performed in the United States during that same time. However, many in the United States had the impression that girls had been maturing earlier than in the past.

No data were available to confirm this impression until 1997, when Herman-Giddens et al reported on the incidence of breast and pubic hair development by age and race in 17,000 US girls aged 3-12 years.[4] They used the established definition that breast or pubic development in girls was precocious before age 8 years and estimated that approximately 8% of white and 25% of black girls in the United States exhibited evidence of sexual precocity. The results of this study are illustrated in the images below.

Graph represents the prevalence of breast developm Graph represents the prevalence of breast development at Tanner stage 2 or greater by age and race.
Graph represents the prevalence of pubic hair at T Graph represents the prevalence of pubic hair at Tanner stage 2 or greater by age and race.

In 1999, as a result of the Herman-Giddens study, Kaplowitz and Oberfield published new guidelines recommending that puberty be considered precocious only when breast development or pubic hair appear before age 7 years in white girls and age 6 years in black girls.[5] However, most clinicians continue to use the 8 year definition.

In 2010, a new study by Biro et al reported that in a cohort of 1239 girls aged 7-7.99 years from 3 urban centers, the proportion who had reached Tanner 2 breast development was 10.4% of white girls, 23.4% of black girls, and 14.9% of Hispanic girls.[6] While this was a cross-sectional study and it was not clear what proportion of these girls had progressive precocious puberty, the study confirmed that in the United States, the appearance of breast development prior to age 8 years is quite common.

Reliable estimates of the frequency of precocious puberty in boys have not been published. However, several centers have reported that they evaluate between one fifth and one tenth as many boys as girls for sexual precocity. Whether early puberty in boys is becoming more common over time, as is the case in girls, is unclear. However, a study from Denmark found that the mean age of testicular enlargement in boys declined from age 11.92 years to 11.66 years between 1991-1993 and 2006-2008, suggesting that more boys may be starting puberty before age 9 years.[7]


A review of trends in timing of puberty around the world showed no clear trend toward earlier puberty in northern Europe, but earlier mean age of menarche has been reported in some southern European countries and other warmer parts of the world.[8] A report from Denmark showed that over a 15-year period (1991-1993 vs 2000-2008), the mean age at which breast tissue appeared in girls decreased from age 10.88 years to 9.86 years, with a much smaller decline in the mean age at menarche (age 13.42 y vs age 13.13 y).[9] A study of over 20,000 girls from urban China done from 2003-2005 show that the mean age of breast development was 9.2 years, with the mean age at menarche falling to 12.27 years; about 20% of 8-year-old girls already had evidence of breast development.[10] Thus, in certain parts of the world, a decline in the age of puberty in girls has been noted, with parallel changes seen in US girls.

An interesting and still unexplained finding is the high incidence of precocious puberty in girls adopted into Western Europe from various underdeveloped countries. This has been studied extensively in Denmark, where the mean age at thelarche and at menarche in international adopted girls was significantly lower than that observed in a reference group of Danish-born girls.[11] Exposure to chemicals in the environment has been proposed as the cause, but the fact that LH, FSH, and estradiol levels rise earlier in adopted girls suggest that their earlier puberty is centrally mediated and not chemically induced.


Isolated sexual precocity of unknown etiology carries no increased risk of mortality; however, distinguishing between children with idiopathic central precocious puberty and the rare patient with a CNS, adrenal, or ovarian tumor is important because the latter group may be at risk for tumor-related complications. Some, but not all, studies have found an association between early puberty in girls and a higher risk of breast cancer.

Children with precocious puberty may be stressed because of physical and hormonal changes they are too young to understand. They may be teased by their peers because of their physical difference. Girls who reach menarche before age 9-10 may become withdrawn and may have difficulty adjusting to wearing and changing pads. Both sexes, but more so boys than girls, may have increases in libido leading to increased masturbation or inappropriate sexual behaviors at a young age. Girls with a history of early puberty have a slightly earlier age of initiation of sexual activity.

Some studies have found that children with precocious puberty more frequently exhibit behavioral problems and are less socially competent than age-matched peers. Some, but not all, studies find evidence of emotional problems persisting into adulthood. The distress associated with early menses can be decreased if parents are encouraged to prepare their daughters for this event when they reach stage III-IV of breast development.

Early puberty accelerates growth. These children may initially be considerably taller than their peers. Because bone maturation is also accelerated, growth may be completed at an unusually early age, resulting in short stature. Short stature is more likely if puberty starts very early (ie, before age 6 y) than if it begins moderately early (ie, ages 6-8 y). Several studies show that most untreated girls with idiopathic central precocious puberty reach an adult height within the reference range. Determination of bone age can be used to predict adult height and to select patients with high risk for short stature if left untreated.


The study by Herman-Giddens et al and the data from the National Health and Nutrition Examination Survey (NHANES) III study conclusively showed that black girls in the United States have onset of breast development and pubic hair about one year earlier than white girls; thus, using the same age definition of precocious puberty for white and black girls yields a higher incidence in black girls.[4, 12] No current evidence shows that black boys mature earlier than white boys; thus, incidence of precocious puberty among boys is similar in both races. The NHANES III study indicated that Mexican-American girls start breast development at a similar age as white girls, and that pubic hair appears slightly later.[12]


In a series of more than 200 patients evaluated at a single medical center, central precocious puberty occurred 5 times more often in girls than boys.[13] Idiopathic central precocious puberty occurred 8 times more often. A possible explanation for this difference is that many girls whose puberty is considered precocious are actually healthy girls at the early end of the normal distribution.


If precocious puberty in females (mostly central) is defined as the early onset of breast development, then the data of Herman-Giddens et al can be used to estimate frequency of central precocious puberty at different ages in both white girls and black girls. Be cautious, however, in equating breast development in 3-year-olds with central precocious puberty because most such girls actually have premature thelarche, a benign normal variant (see Differentials). The younger the age of girls with proven central precocious puberty, the higher the likelihood of serious underlying disorder.



Without treatment

See the list below:

  • Most girls with early puberty who are aged 6-8 years at the onset of puberty achieve an adult height within the reference range. Treatment with GnRH analogues such as Lupron is usually associated with only a modest gain in final height in this age group.
  • Consider therapy following initial evaluation for girls who then have predicted heights less than 4 ft 11 in or who are well below their target height (ie, average of parents' heights, less 2.5 in) when the patient also has very advanced bone age, a height below the 25th percentile, or both.
  • Controversy surrounds the significance of several studies (mostly with small numbers of patients with no control group) that appear to indicate that girls with central precocious puberty are at increased risk for significant behavior problems, such as poor self-esteem and higher anxiety, irritability, or withdrawal. Other studies have not shown such problems. A recent review of this topic by Walvoord and Mazur concluded that central precocious puberty may become a risk factor for psychosocial problems, mainly in the setting of other risk factors; they cautioned against medical therapy in order to avoid presumed negative psychological consequences of precocious puberty. [14]

With treatment

See the list below:

  • Most studies show significant improvement in adult height compared with height predicted at the start of therapy, but the extent of this improvement depends to some extent on the age of onset of central precocious puberty.
  • A recent study from Israel showed that height gained in girls after discontinuation of GnRH analogue therapy at age 11-12 years (and bone age 12-12.5 y) is greater for girls with onset of central precocious puberty before age 6 years than at age 6-8 years or after age 8 years. Mean final height was better than genetic target height in the younger group and less-than-target height in the group whose puberty started after age 8 years. [15]  This supports the view that the benefit of treatment in terms of increased adult height is the greatest in patients who are diagnosed with central precocious puberty and started on GnRH analogues at younger ages.
  • Normal adult height can be achieved in most cases if treatment is started before bone maturation is too advanced (>12 y in girls, >13 y in boys) and if good gonadal suppression is maintained for several years. Treatment allows growth to continue while dramatically slowing the rate of bone maturation.
Contributor Information and Disclosures

Paul B Kaplowitz, MD, PhD Professor of Pediatrics, George Washington University School of Medicine and Health Sciences; Chief of Endocrinology, Children's National Medical Center

Paul B Kaplowitz, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, Endocrine Society, Pediatric Endocrine Society

Disclosure: Nothing to disclose.

Specialty Editor Board

Mary L Windle, PharmD Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Lynne Lipton Levitsky, MD Chief, Pediatric Endocrine Unit, Massachusetts General Hospital; Associate Professor of Pediatrics, Harvard Medical School

Lynne Lipton Levitsky, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics, American Diabetes Association, American Pediatric Society, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Received grant/research funds from Eli Lilly for pi; Received grant/research funds from NovoNordisk for pi; Received consulting fee from NovoNordisk for consulting; Partner received consulting fee from Onyx Heart Valve for consulting.

Chief Editor

Stephen Kemp, MD, PhD Former Professor, Department of Pediatrics, Section of Pediatric Endocrinology, University of Arkansas for Medical Sciences College of Medicine, Arkansas Children's Hospital

Stephen Kemp, MD, PhD is a member of the following medical societies: American Academy of Pediatrics, American Association of Clinical Endocrinologists, American Pediatric Society, Endocrine Society, Phi Beta Kappa, Southern Medical Association, Southern Society for Pediatric Research

Disclosure: Nothing to disclose.

Additional Contributors

Phyllis W Speiser, MD Chief, Division of Pediatric Endocrinology, Steven and Alexandra Cohen Children's Medical Center of New York; Professor of Pediatrics, Hofstra-North Shore LIJ School of Medicine at Hofstra University

Phyllis W Speiser, MD is a member of the following medical societies: American Association of Clinical Endocrinologists, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research

Disclosure: Nothing to disclose.

  1. Chalumeau M, Chemaitilly W, Trivin C, et al. Central precocious puberty in girls: an evidence-based diagnosis tree to predict central nervous system abnormalities. Pediatrics. 2002 Jan. 109(1):61-7. [Medline]. [Full Text].

  2. Ng SM, Kumar Y, Cody D, et al. Cranial MRI scans are indicated in all girls with central precocious puberty. Arch Dis Child. 2003 May. 88(5):414-8; discussion 414-8. [Medline]. [Full Text].

  3. Marshall WA, Tanner JM. Variations in pattern of pubertal changes in girls. Arch Dis Child. 1969 Jun. 44(235):291-303. [Medline].

  4. Herman-Giddens ME, Slora EJ, Wasserman RC, et al. Secondary sexual characteristics and menses in young girls seen in office practice: a study from the Pediatric Research in Office Settings network. Pediatrics. 1997 Apr. 99(4):505-12. [Medline]. [Full Text].

  5. [Guideline] Kaplowitz PB, Oberfield SE. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: implications for evaluation and treatment. Drug and Therapeutics and Executive Committees of the Lawson Wilkins Pediatric Endocrine Society. Pediatrics. 1999 Oct. 104(4 Pt 1):936-41. [Medline]. [Full Text].

  6. Biro FM, Galvez MP, Greenspan LC, Succop PA, Vangeepuram N, Pinney SM. Pubertal assessment method and baseline characteristics in a mixed longitudinal study of girls. Pediatrics. 2010 Sep. 126(3):e583-90. [Medline].

  7. Sorensen K, Aksglaede L, Petersen JH, Juul A. Recent changes in pubertal timing in healthy Danish boys: associations with body mass index. J Clin Endocrinol Metab. 2010 Jan. 95(1):263-70. [Medline].

  8. Parent AS, Teilmann G, Juul A, et al. The timing of normal puberty and the age limits of sexual precocity: variations around the world, secular trends, and changes after migration. Endocr Rev. 2003 Oct. 24(5):668-93. [Medline]. [Full Text].

  9. Aksglaede L, Sorensen K, Petersen JH, et al. Recent decline in age at breast development: the Copenhagen Puberty Study. Pediatrics. 2009 May. 123(5):e932-9. [Medline].

  10. Ma HM, Du ML, Luo XP, et al. Onset of breast and pubic hair development and menses in urban Chinese girls. Pediatrics. 2009 Aug. 124(2):e269-77. [Medline].

  11. Teilmann G, Petersen JH, Gormsen M, Damgaard K, Skakkebaek NE, Jensen TK. Early puberty in internationally adopted girls: hormonal and clinical markers of puberty in 276 girls examined biannually over two years. Horm Res. 2009. 72(4):236-46. [Medline].

  12. Wu T, Mendola P, Buck GM. Ethnic differences in the presence of secondary sex characteristics and menarche among US girls: the Third National Health and Nutrition Examination Survey, 1988-1994. Pediatrics. 2002 Oct. 110(4):752-7. [Medline]. [Full Text].

  13. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. Arch Dis Child. 1994 Feb. 70(2):116-8. [Medline].

  14. Walvoord EC, Mazur T. Behavioral problems and idiopathic central precocious puberty: Fact or fiction?. Pediatr Endocrinol Rev. June 2007. 4 (suppl 3):306-12.

  15. Lazar L, Padoa A, Phillip M. Growth pattern and final height after cessation of gonadotropin-suppressive therapy in girls with central sexual precocity. J Clin Endocrinol Metab. 2007 Sep. 92(9):3483-9. [Medline].

  16. [Guideline] American Academy of Pediatrics. Sexuality education for children and adolescents: Committee on Psychosocial Aspects of Child and Family Health and Committee on Adolescence. Pediatrics. 2001 Aug. 108(2):498-502.

  17. de Vries L, Kauschansky A, Shohat M, Phillip M. Familial central precocious puberty suggests autosomal dominant inheritance. J Clin Endocrinol Metab. 2004 Apr. 89(4):1794-800. [Medline]. [Full Text].

  18. Mamun AA, Hayatbakhsh MR, O'Callaghan M, Williams G, Najman J. Early overweight and pubertal maturation--pathways of association with young adults' overweight: a longitudinal study. Int J Obes (Lond). 2009 Jan. 33(1):14-20. [Medline].

  19. Frisch RE, McArthur JW. Menstrual cycles: fatness as a determinant of minimum weight for height necessary for their maintenance or onset. Science. 1974 Sep 13. 185(4155):949-51. [Medline].

  20. Lee JM, Appugliese D, Kaciroti N, et al. Weight status in young girls and the onset of puberty. Pediatrics. 2007 Mar. 119(3):e624-30. [Medline].

  21. Currie C, Ahluwalia N, Godeau E, Nic Gabhainn S, Due P, Currie DB. Is Obesity at Individual and National Level Associated With Lower Age at Menarche? Evidence From 34 Countries in the Health Behaviour in School-aged Children Study. J Adolesc Health. 2012 Jun. 50(6):621-6. [Medline].

  22. Reiter EO, Saenger P. Premature adrenarche. The Endocrinologist. 1997. 7:85-88.

  23. Stephen MD, Jehaimi CT, Brosnan PG, Yafi M. Sexual precocity in a 2-year-old boy caused by indirect exposure to testosterone cream. Endocr Pract. 2008 Nov. 14(8):1027-30. [Medline].

  24. Armengaud JB, Charkaluk ML, Trivin C, Tardy V, Bréart G, Brauner R. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab. 2009 Aug. 94(8):2835-40. [Medline].

  25. Resende EA, Lara BH, Reis JD, Ferreira BP, Pereira GA, Borges MF. Assessment of basal and gonadotropin-releasing hormone-stimulated gonadotropins by immunochemiluminometric and immunofluorometric assays in normal children. J Clin Endocrinol Metab. 2007 Apr. 92(4):1424-9. [Medline].

  26. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. Pediatrics. 2009 Jun. 123(6):e1059-63. [Medline].

  27. [Guideline] Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009 Apr. 123(4):e752-62. [Medline].

  28. Sathasivam A, Garibaldi L, Shapiro S, Godbold J, Rapaport R. Leuprolide Stimulation Testing for the Evaluation of Early Female Sexual Maturation. Clin Endocrinol (Oxf). 2010 Feb 23. [Medline].

  29. Liu S, Liu Q, Cheng X, Luo Y, Wen Y. Effects and safety of combination therapy with gonadotropin-releasing hormone analogue and growth hormone in girls with idiopathic central precocious puberty: a meta-analysis. J Endocrinol Invest. 2016 May 25. [Medline].

  30. Wang M, Zhang Y, Lan D, Hill JW. The Efficacy of GnRHa Alone or in Combination with rhGH for the Treatment of Chinese Children with Central Precocious Puberty. Sci Rep. 2016 Apr 13. 6:24259. [Medline]. [Full Text].

  31. Fuld K, Chi C, Neely EK. A randomized trial of 1- and 3-month depot leuprolide doses in the treatment of central precocious puberty. J Pediatr. 2011 Dec. 159(6):982-7.e1. [Medline].

  32. Eugster EA, Clarke W, Kletter GB, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab. 2007 May. 92(5):1697-704. [Medline].

  33. Kaplowitz P. Clinical characteristics of 104 children referred for evaluation of precocious puberty. J Clin Endocrinol Metab. 2004 Aug. 89(8):3644-50. [Medline]. [Full Text].

  34. Kaplowitz P. Precocious puberty: update on secular trends, definitions, diagnosis, and treatment. Adv Pediatr. 2004. 51:37-62. [Medline].

  35. Kaplowitz PB, Slora EJ, Wasserman RC, et al. Earlier onset of puberty in girls: relation to increased body mass index and race. Pediatrics. 2001 Aug. 108(2):347-53. [Medline]. [Full Text].

  36. Kletter GB, Kelch RP. Clinical review 60: Effects of gonadotropin-releasing hormone analog therapy on adult stature in precocious puberty. J Clin Endocrinol Metab. 1994 Aug. 79(2):331-4. [Medline].

  37. Lee PA. Laboratory monitoring of children with precocious puberty. Arch Pediatr Adolesc Med. 1994 Apr. 148(4):369-76. [Medline].

  38. Neely EK, Wilson DM, Lee PA, et al. Spontaneous serum gonadotropin concentrations in the evaluation of precocious puberty. J Pediatr. 1995 Jul. 127(1):47-52. [Medline].

  39. Pescovitz OH, Comite F, Hench K, et al. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy. J Pediatr. 1986 Jan. 108(1):47-54. [Medline].

  40. Junqueira FR, Lara LA, Martins WP, Ferriani RA, Rosa-E-Silva AC, et al. Gonadotropin and Estradiol Levels after Leuprolide Stimulation Tests in Brazilian Girls with Precocious Puberty. J Pediatr Adolesc Gynecol. 2015 Oct. 28 (5):313-6. [Medline].

  41. Iannetta R, Melo AS, Iannetta O, Marchini JS, Paula FJ, et al. Use of a Gonadotropin-releasing Hormone Analog to Treat Idiopathic Central Precocious Puberty Is Not Associated with Changes in Bone Structure in Postmenarchal Adolescents. J Pediatr Adolesc Gynecol. 2015 Oct. 28 (5):304-8. [Medline].

  42. Catlı G, Erdem P, Anık A, Abacı A, Bober E. Clinical and laboratory findings in the differential diagnosis of central precocious puberty and premature thelarche. Turk Pediatri Ars. 2015 Mar. 50 (1):20-6. [Medline].

Graph represents the prevalence of breast development at Tanner stage 2 or greater by age and race.
Graph represents the prevalence of pubic hair at Tanner stage 2 or greater by age and race.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.